We showed that a plant-derived FGF21-transferrin fusion protein can be used for oral delivery of FGF21 as a potential therapeutic of NASH and provide an initial comparison of different production options and associated costs in transgenic seeds and leaves which both might be used for oral delivery. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.